Pfizer raises 2026 forecasts as Eliquis and cancer drugs drive third-quarter results
The upgraded guidance extends a broad pharma earnings windfall as Pfizer leans on its anticoagulant and oncology portfolio to offset pipeline pruning.
Reuters · +13 outlets
Celltrion unveils world's first quadruple-action obesity drug, plans global trials next year
The Korean company claims its four-hormone candidate beats triple-action rivals while preserving muscle, positioning it in the crowded obesity race.
머니투데이 · +6 outlets
FDA grants uniQure's Huntington's gene therapy priority review, calls it a defining milestone
A priority review shortens the agency's decision timeline for what would be the first gene therapy for the inherited neurodegenerative disease.
Fierce Biotech · +1 outlets
FDA advisers narrowly vote to add six peptides to a drug compounding list
The close vote could open the door for compounded versions of popular peptide therapies, a closely watched front in the GLP-1 supply battle.
The American Journal of Managed Care · +7 outlets
Pfizer pares back obesity pipeline, drops phase 2-stage lung disease candidate
The cuts show the company trimming early-stage programs even as it pushes into China's obesity market and touts its late-stage portfolio.
Fierce Biotech · +1 outlets
Lilly's Jaypirca wins FDA approval for first-line CLL/SLL treatment
The expanded label moves the BTK inhibitor into front-line use for chronic lymphocytic leukemia and small lymphocytic lymphoma.
scanx.trade · +6 outlets
FDA places partial clinical hold on Bright Minds' BMB-101 epilepsy trial over mouse toxicity
The hold on the Phase 2 seizure study clouds the biotech's lead program after animal toxicity findings.
Yahoo Finance · +9 outlets
Sun Pharma gets approval to manufacture and market generic semaglutide pill in India
The nod marks a major step for low-cost oral GLP-1 competition in one of the world's largest generic markets.
NAVLIN DAILY · +7 outlets
India's NPPA cuts MRPs on 1,085 anti-cancer drugs, patients seen saving Rs 2,500-3,500 crore a year
Experts applaud the pricing move but say bigger access concerns remain, while AstraZeneca won a court reprieve from NPPA action.
The Economic Times · +4 outlets
Clinical trial investigators write to FDA urging approval of Capricor's Deramiocel
The unusual investigator letter pressures the agency ahead of a decision on the Duchenne muscular dystrophy cell therapy.
Stocktwits · +1 outlets
Lilly's R&D reshuffle: what the large pharma has taken in and dropped
The review of Lilly's dealmaking comes as its weight-loss franchise pushes the stock toward record highs and attention shifts to hair loss assets.
Pharma Voice · +3 outlets
TiumBio's Tosposertib receives FDA fast track designation for head and neck cancer
The designation could speed development and review of the Korean biotech's candidate in a cancer type with limited options.
아시아경제
Korean obesity drug Efpe launches around 180,000 won for first four weeks, undercutting Mounjaro
Domestic pricing data show the homegrown therapy undercutting imported rivals by 26 to 44 percent as Korea's obesity market intensifies.
재경일보 · +3 outlets
Keytruda biosimilars approach but face an uphill commercial battle
The coming wave of biosimilars to Merck's blockbuster faces entrenched payer and prescribing patterns.
BioPharma Dive · +2 outlets
Pfizer leans on Viagra model to compete in China's obesity market
The company is betting its late entrant status in China can be offset by consumer-branding tactics previously used for erectile dysfunction drugs.
BioSpace · +1 outlets
China leads Asia-Pacific obesity drug race as South Korea chases with six candidates
Both countries are accelerating GLP-1 and related programs, with Chinese developers currently ahead in the regional race.
Chosunbiz
Denali's $70.1M profit includes one-time $194M gain from selling priority review voucher
The voucher sale illustrates how rare pediatric disease review incentives have become a material revenue source for biotechs.
Stock Titan
Ultragenyx to sell two FDA approval priority review vouchers for $413 million
The deal is one of the largest such voucher sales, converting rare disease approvals into upfront cash.
Stock Titan